Keywords
cutaneous squamous cell carcinoma, cetuximab, EGFR, non-melanoma skin cancer
cutaneous squamous cell carcinoma, cetuximab, EGFR, non-melanoma skin cancer
This case describes the effective use of cetuximab in an extensive thoracic cutaneous squamous cell carcinoma resistant to all previous lines of chemotherapy.
Non-melanoma skin cancer (NMSC) is the most common malignant neoplasm affecting Caucasian individuals, the main types of which are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). SCC has a lower incidence than BCC and the gold standard of treatment is surgical excision. Between 1–5% of SCCs exhibit biologically aggressive behavior and are resistant to surgery1.
The management of metastatic or locally advanced SCC includes radiotherapy (alone or in combination with surgery) and systemic chemotherapy, but a consensus for the treatment of cutaneous SCC (cSCC) is still lacking. cSCCs that don’t respond to conventional treatments pose a further challenge and may benefit from the use of target therapy, such as inhibitors of the epidermal growth factor receptor (EGFR) pathway and immunotherapy with checkpoint inhibitors2.
Cetuximab is a monoclonal antibody first approved for metastatic colon-rectal carcinoma with EGFR expression. EGFR is also overexpressed in the majority of SCCs and the drug is indicated, in association with radiotherapy, for locally advanced head-neck SCC, or with chemotherapy for recurrent/metastatic disease. It is normally used at the standard weekly dosage of 250mg/m2. Cetuximab use is currently off-label for cSCC in different skin sites. Current literature supports the use of monoclonal antibodies and oral agents targeting EGFR in advanced cSCC3.
A 60-year-old Caucasian man, currently unemployed, presented to our dermatology department complaining of the recurrence of a thoracic cSCC. Physical examination revealed an extensive ulcerative skin lesion of the sternal area covered by necrotic and fibrinous tissue. The patient reported intermittent pain and bleeding (Figure 1).
The onset of a nodular skin lesion in the same site dated back to 2000, but an initial diagnosis of BCC was made only in 2013, when a single biopsy was performed (see Table 1 for timeline). A computerized tomography (CT) scan followed, demonstrating a high local burden of disease, with destructive osteo-muscular infiltration, preventing a surgical or radiation approach, and the patient was treated with vismodegib (150 mg daily). After 12 months of apparent clinical remission, a local relapse was observed, and the histologic examination of an excisional biopsy diagnosed SCC. Surgical removal of the tumor was not radical, and the patient was referred for adjuvant chemotherapy, failing four consecutive cytotoxic regimens, until the personal decision of the patient to withdraw from treatment. The four regimens were as follows: cisplatinum 100mg/m2 on day one with fluorouracil 1000mg/m2 on days 1–4 of 21-day cycles for three cycles; radio-chemotherapy with gemcitabine 3000mg/m2 on days one and 15 of 28-day-cycles; cisplatinum 100mg/m2 and docetaxel 75mg/m2 on day one of 21-day-cycles; and monotherapy with gemcitabine 3000mg/m2 on days one and 15 of 28-day-cycles for eight cycles.
A stage III-disease (T3N0M0, Figure 2a)4 progressing through several lines of conventional chemotherapy advised the use of targeted and immunological therapies. First, immunohistochemistry for tissue levels of programmed cell death ligand 1 (PD-L1) was performed on the previous biopsy sample documenting no/low expression. We resorted to cetuximab, the use of which is off-label for cSCC. We administered cetuximab at an initial single dose of 400mg/m2, followed by 250mg/m2 every week, the standard dosing approved for SCC of the head-neck district, for seven cycles and every two weeks for six more cycles. The patient was staged after six and 12 weeks with a whole-body CT scan, documenting stability in the size and radiologic features of the disease. (Figure 2b and 2c).
Therapy with cetuximab is ongoing and we plan to restage the patient after three months. Future management of our patient includes ongoing treatment with cetuximab or evaluation for therapy with programmed cell death protein-1 (PD-1) inhibitors.
The results of our report encourage the use of cetuximab in this setting. However, data on long-term efficacy is lacking and we are not able to predict duration of response.
Treatment options for locally invasive or metastatic SCC include systemic chemotherapy, adjuvant chemo-radiotherapy, as well as inhibitors of the EGFR pathway and immunotherapy with checkpoint inhibitors, which are the latest additions2. Systemic drugs for the treatment of cSCC are used off-label and the established regimens, mainly cisplatinum-based combinations, are those that were administered to our patient5,6.
Response to second line-therapy, after failure of the first line regimen, is generally uncommon and evidence of prolonged survival is lacking. Prior treatment history, the patient’s general condition and toxicity profiles guide the choice of second-line cytotoxic agent. Gemcitabine has shown activity in previously treated subjects and was employed in our patient with radiotherapy and as single agent7.
We were challenged to select an effective treatment in this advanced case and resorted to EGFR inhibitor therapy on the biological notion that EGFR is overexpressed in over 90% of cSCC. A phase II study of unresectable cSCC treated with cetuximab for at least six weeks registered 25% objective response and 42% disease stabilization8. Cetuximab is approved for the treatment of locally or regional advanced SCC of the head and neck region (in combination with radiation) or for recurrent or metastatic disease (alone or in association with platinum). Its use in cSCC of other regions is currently off-label but our choice of drug was extensively supported by evidence in published literature3.
A novel attractive approach is immune checkpoint inhibition in the context of cSCC, with monoclonal antibody cemiplimab currently undergoing registration for the treatment of cSCC9. Cancer immune surveillance is crucial to the development of cSCC, as demonstrated by the high frequency of cSCC in immunosuppressed patients. PD-1 inhibitors stimulate an anti-cancer immune response and their use in dermatology is established for the treatment of metastatic melanoma. In this case, PD-L1 expression was assessed through immunohistochemistry and low/no expression was found. Mucosal head-neck SCCs display high expression of PD-L1 in the majority of cases10; however, the role of tumor PD-L1 expression in predicting response to therapy has not been demonstrated and low expression does not contraindicate immunotherapy, even if PD-L1 negative tumors correlate to poorer prognosis and lower response to checkpoint inhibitors.
In accordance with published literature11, we support the necessity of taking serial biopsies of extensive epithelial neoplasms to exclude foci of multiple differentiation and believe that a focus of SCC existed prior to therapy with vismodegib and was responsible for the subsequent recurrence and evolution of disease.
Serial biopsies are mandatory for advanced BCC candidates prior to vismodegib treatment.
No drugs are currently approved specifically for cSCC, so all treatments are administered off-label.
The potential efficacy of cetuximab is based on the biological similarity of cSCC to mucosal SCCs of the head-neck district.
Low PD-L1 expression does not preclude the efficacy of checkpoint inhibitors.
All data underlying the results are available as part of the article and no additional source data are required.
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.
Associazione Romana Ricerca Dermatologica covered the publication fees of this article as support to the authors.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
No
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
References
1. Migden M, Rischin D, Schmults C, Guminski A, et al.: PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New England Journal of Medicine. 2018; 379 (4): 341-351 Publisher Full TextCompeting Interests: I consult for Regeneron and Sanofi who manufacture and market Cemiplimab
Reviewer Expertise: Medical oncology.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 31 Dec 19 |
read | read |
Version 1 21 Jun 19 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)